SLCO1B1 gene single nucleotide polymorphism is a drug response marker for pancreatic cancer patients treated with gemcitabine

被引：0
|
作者：
Ueno, H. [1 ]
Ioka, T. [2 ]
Ohkawa, S. [3 ]
Ikeda, M. [4 ]
Shimamura, T. [5 ]
Tsuji, A. [6 ]
Tsuchiya, Y. [7 ]
Okusaka, T. [1 ]
Yoshida, T. [8 ]
Sato, Y. [9 ]
机构：
[1] Natl Canc Ctr, Hepatobiliary & Pancreat Oncol Div, Tokyo, Japan
[2] Osaka Med Ctr Canc & Cardiovasc Dis, Div Hepatobiliary & Pancreat Oncol, Osaka, Japan
[3] Kanagawa Canc Ctr, Div Gastroenterol, Kawasaki, Kanagawa, Japan
[4] Natl Canc Ctr Hosp East, Div Hepatobiliary & Pancreat Oncol, Chiba, Japan
[5] Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan
[6] Kochi Hlth Sci Ctr, Dept Clin Oncol, Kochi, Japan
[7] Niigata Canc Ctr Hosp, Div Surg, Niigata, Japan
[8] Natl Canc Ctr, Div Genet, Tokyo, Japan
[9] Chiba Univ Hosp, Clin Res Ctr, Chiba, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2582
引用
收藏
页码：S613 / S613
页数：1
相关论文
共 50 条
  • [1] SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1
    Sato, Yasunori
    Ueno, Hideki
    Ioka, Tatsuya
    Ohkawa, Shinichi
    Ikeda, Masafumi
    Shimamura, Tomotaka
    Tsuji, Akihito
    Tsuchiya, Yoshiaki
    Furuse, Junji
    Ishii, Hiroshi
    Furuya, Ken
    Iguchi, Haruo
    Saito, Yoshihiro
    Kaniwa, Nahoko
    Sawada, Jun-ichi
    Sakamoto, Hiromi
    Sekine, Akihiro
    Okusaka, Takuji
    Yoshida, Teruhiko
    PANCREAS, 2018, 47 (05) : 637 - 642
  • [2] The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin
    Martin, Nicholas G.
    Li, Ka Wah
    Murray, Heather
    Putt, Wendy
    Packard, Chris J.
    Humphries, Steve E.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (02) : 303 - 306
  • [3] THE EFFECT OF SLCO1B1 GENE POLYMORPHISM ON THE ATORVASTATIN EFFECTIVENESS IN PATIENTS WITH CARDIOVASCULAR DISEASES
    Nurpeissova, Altyn
    Karabayeva, Raushan
    ATHEROSCLEROSIS, 2024, 395
  • [4] Influence of SLCO1B1 in gastric cancer patients treated with EOF chemotherapy
    Feng, Wanjing
    Liu, Xin
    Zhao, Xiaoying
    Huang, Mingzhu
    Guo, Weijian
    Yin, Jiliang
    Chen, Zhiyu
    Zhu, Xiaodong
    ONCOLOGY LETTERS, 2018, 16 (04) : 4489 - 4497
  • [5] Effect of single-nucleotide polymorphism in SLCO1B1 and CDA genes on response and toxicity of induction chemotherapy in acute myeloid leukemia
    Hamdy, Sara
    El Ghandour, Ashraf
    Zaki, Nadia
    Abdelfattah, Fatma
    Tahoun, Mona
    EGYPTIAN JOURNAL OF HAEMATOLOGY, 2024, 49 (01): : 22 - 28
  • [6] SLCO1B1 Polymorphism and Oral Antidiabetic Drugs
    Kalliokoski, Annikka
    Neuvonen, Pertti J.
    Niemi, Mikko
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2010, 107 (04) : 775 - 781
  • [7] Analysis of APOE and SLCO1B1 Gene Polymorphism and Correlation with Dyslipidemia in China
    Long, Lu
    Sun, Qian
    CLINICAL LABORATORY, 2022, 68 (11) : 2310 - 2315
  • [8] The impact of SLCO1B1 single nucleotide polymorphism and non-genetic factors on statin-induced myopathy
    Alaryan, T. H.
    Youssef, L.
    CARDIOVASCULAR RESEARCH, 2024, 120
  • [9] Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1)
    Niemi, M
    Kivistö, KT
    Hofmann, U
    Schwab, M
    Eichelbaum, M
    Fromm, MF
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) : 602 - 604
  • [10] FREQUENCIES OF SINGLE-NUCLEOTIDE POLYMORPHISMS AND HAPLOTYPES OF THE SLCO1B1 GENE IN SELECTED POPULATIONS OF THE WESTERN BALKANS
    Grapci, Daka A.
    Dimovski, A. J.
    Kapedanovska, A.
    Vavlukis, M.
    Eftimov, A.
    Geshkovska, Matevska N.
    Labachevski, N.
    Jakjovski, K.
    Gorani, D.
    Kedev, S.
    Mladenovska, K.
    BALKAN JOURNAL OF MEDICAL GENETICS, 2015, 18 (01) : 5 - 21
12345